Article info
PDFHepatology
Paper
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
- Correspondence to Rami Moucari, Service d'Hépatologie et INSERM U773-CRB3, Hôpital Beaujon, Clichy, France; rmoucari{at}yahoo.com
Citation
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C
Publication history
- Revised June 25, 2010
- Accepted June 30, 2010
- First published September 21, 2010.
Online issue publication
January 24, 2018
Article Versions
- Previous version (24 January 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.